Physician profile
Dylan Harrell
NPI 1679936769
$3,961.59
in general payments reported to CMS, 2019-2025
30 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $1,173 · 2024: $932 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,504 · Travel and Lodging: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.05 |
| Travel and Lodging | $1,333.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,494.79 | 2023-2025 | Da Vinci Surgical System |
| Olympus America INC. | $493.72 | 2024-2025 | Spiration Valve System |
| Glaxosmithkline, LLC. | $374.83 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $331.15 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Shionogi INC | $217.44 | 2022-2023 | Fetroja |
| Actelion Pharmaceuticals US, INC. | $127.04 | 2024-2025 | Opsumit, Opsynvi, Uptravi |
| Genzyme Corporation | $122.98 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $96.04 | 2023-2025 | Dupixent, Libtayo |
| Merck Sharp & Dohme LLC | $78.77 | 2024-2025 | Zerbaxa |
| Insmed, INC. | $73.55 | 2023-2025 | Arikayce |
| Body Vision Medical INC. | $71.67 | 2024 | Lungvision |
| Gyrus Acmi, INC. | $59.58 | 2025 | Spiration Valve System |
| Genentech USA, INC. | $48.20 | 2024-2025 | Tecentriq, Alecensa |
| Jazz Pharmaceuticals INC. | $46.34 | 2024 | |
| Electromed, INC. | $33.25 | 2025 | Smartvest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.10 | 2024-2025 | Glassia |
| Pinnacle Biologics, INC | $27.53 | 2024 | Photofrin |
| Bayer Healthcare Pharmaceuticals INC. | $26.11 | 2025 | |
| Abbvie INC. | $24.58 | 2025 | |
| Daiichi Sankyo INC. | $22.84 | 2024 | Enhertu |
| Verona Pharma, INC. | $17.98 | 2025 | Ohtuvayre |
| Abiomed | $17.93 | 2024 | Impella |
| Paratek Pharmaceuticals, INC. | $17.34 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $17.14 | 2024 | Xarelto |
| Philips North America LLC | $16.26 | 2025 | Vest Therapy Und |
| Regeneron Pharmaceuticals, INC. | $15.15 | 2025 | Libtayo |
| Recordati_rare_diseases_inc. | $14.46 | 2025 | Sylvant |
| Pharmacosmos Therapeutics INC. | $14.35 | 2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $13.99 | 2023 | Rezlidhia, Tavalisse |
| Emd Serono, INC. | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.